Compare Natera Inc. Common Stock (NTRA) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Williams-Sonoma, Inc. — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Williams-Sonoma, Inc. trades at $244 (market cap $28.26B). The key difference: Natera Inc. Common Stock is far larger — about 2× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Williams-Sonoma, Inc. for 59 Days on average.
| NTRA | WSM | |
|---|---|---|
Market Cap | $57.03B | $28.26B |
Volume | 1,131,157 | 1,108,410 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $251.81 |
52-Week Low | $179.42 | $168.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $56.18B | $28.76B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Williams-Sonoma (WSM) trades at $239.98, up 0.47% today, reflecting strong momentum near its consensus price target of $246.31. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.10 versus $2.08 expected. Fundamentals are robust with a net income margin of 14.73% and ROE of 54.96%, supported by strategic initiatives like new store openings and collaborations.
The outlook remains positive with raised full-year guidance and market share gains in a flat industry, though risks include housing market sensitivity and high valuation multiples. Analyst consensus leans Hold (57.15%) with upside potential to the high target of $275, but investor caution is warranted given the stock's premium pricing and economic cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
